SOUTH SAN FRANCISCO, Calif.,
Jan. 7, 2022 /PRNewswire/
-- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported
the grant of stock options to purchase an aggregate of 610,000
shares of common stock to 14 newly hired employees. These awards
were approved by the Compensation Committee of Rigel's Board of
Directors and granted pursuant to the Rigel Pharmaceuticals, Inc.
Inducement Plan, as amended, with a grant date of January 6, 2022, as an inducement material to the
new employees entering into employment with Rigel, in accordance
with NASDAQ Listing Rule 5635(c)(4).
The stock options have an exercise price of $2.62 per share, the price at the close of
trading of Rigel's common stock on January
6, 2022. The stock options awards vest over a four-year
period, with one-fourth of the shares subject to such awards
vesting on the first anniversary of the award's vesting
commencement date, and the remaining shares vesting in equal
monthly installments thereafter.
Rigel is providing this information in accordance with NASDAQ
Listing Rule 5635(c)(4).
About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated
to discovering, developing, and providing novel small molecule
drugs that significantly improve the lives of patients with
hematologic disorders, cancer, and rare immune diseases. Rigel's
pioneering research focuses on signaling pathways that are critical
to disease mechanisms. The company's first FDA-approved product is
TAVALISSE® (fostamatinib disodium hexahydrate)
tablets, the only oral spleen tyrosine kinase (SYK) inhibitor for
the treatment of adult patients with chronic immune
thrombocytopenia who have had an insufficient response to a
previous treatment. The product is also commercially available in
Europe (TAVLESSE) and Canada (TAVALISSE) for the treatment of
chronic immune thrombocytopenia in adult patients.
Fostamatinib is currently being studied in a Phase 3 clinical
trial (NCT03764618) for the treatment of warm autoimmune hemolytic
anemia (wAIHA)1; a Phase 3 clinical trial (NCT04629703)
for the treatment of hospitalized high-risk patients with
COVID-191; an NIH/NHLBI-sponsored Phase 3 ACTIV-4 Host
Tissue Study for the treatment of COVID-19 in hospitalized patients
on oxygen therapy, and a Phase 2 clinical trial for the treatment
of COVID-19 being conducted by Imperial College London.
Rigel's other clinical programs include its interleukin
receptor-associated kinase (IRAK) inhibitor program, and a
receptor-interacting serine/threonine-protein kinase (RIP1)
inhibitor program in clinical development with partner Eli Lilly
and Company. In addition, Rigel has product candidates in
development with partners AstraZeneca, BerGenBio ASA, and Daiichi
Sankyo.
For further information, visit www.rigel.com or follow
us on Twitter or LinkedIn.
Please see www.TAVALISSE.com for the full
Prescribing Information.
1The product for this use or indication is
investigational and has not been proven safe or effective by any
regulatory authority.
Investor Contact:
Jodi Sievers
Rigel Pharmaceuticals, Inc.
Phone: 650.624.1232
Email: ir@rigel.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301456588.html
SOURCE Rigel Pharmaceuticals, Inc.